Allergy Therapeutics PLC
LSE:AGY

Watchlist Manager
Allergy Therapeutics PLC Logo
Allergy Therapeutics PLC
LSE:AGY
Watchlist
Price: 11 GBX -2.65% Market Closed
Market Cap: 675.6m GBX

Intrinsic Value

AGY price has not been updated for more than 3 weeks. This may indicate that the stock has been delisted.

The intrinsic value of one AGY stock under the Base Case scenario is 4.97 GBX. Compared to the current market price of 11 GBX, Allergy Therapeutics PLC is Overvalued by 55%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

AGY Intrinsic Value
4.97 GBX
Overvaluation 55%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation History
Allergy Therapeutics PLC

What is Valuation History?
Ask AI Assistant
What other research platforms think about AGY?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is AGY valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Allergy Therapeutics PLC.

Explain Valuation
Compare AGY to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about AGY?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Allergy Therapeutics PLC

Current Assets 34.7m
Cash & Short-Term Investments 12.8m
Receivables 8m
Other Current Assets 13.9m
Non-Current Assets 32.9m
Long-Term Investments 2.8m
PP&E 24.3m
Intangibles 4.3m
Other Non-Current Assets 1.5m
Current Liabilities 27.2m
Accounts Payable 13.6m
Other Current Liabilities 13.6m
Non-Current Liabilities 68.5m
Long-Term Debt 58.2m
Other Non-Current Liabilities 10.3m
Efficiency

Free Cash Flow Analysis
Allergy Therapeutics PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Allergy Therapeutics PLC

Revenue
55m GBP
Cost of Revenue
-25.7m GBP
Gross Profit
29.3m GBP
Operating Expenses
-57.6m GBP
Operating Income
-28.3m GBP
Other Expenses
-11.9m GBP
Net Income
-40.1m GBP
Fundamental Scores

AGY Profitability Score
Profitability Due Diligence

Allergy Therapeutics PLC's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

Exceptional ROE
ROE is Increasing
Exceptional Gross Margin
Strong 3Y Average Gross Margin
30/100
Profitability
Score

Allergy Therapeutics PLC's profitability score is 30/100. The higher the profitability score, the more profitable the company is.

AGY Solvency Score
Solvency Due Diligence

Allergy Therapeutics PLC's solvency score is 30/100. The higher the solvency score, the more solvent the company is.

Low D/E
Short-Term Solvency
Long-Term Solvency
Positive Net Debt
30/100
Solvency
Score

Allergy Therapeutics PLC's solvency score is 30/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

AGY Price Targets Summary
Allergy Therapeutics PLC

Wall Street analysts forecast AGY stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for AGY is 13.26 GBX with a low forecast of 13.13 GBX and a high forecast of 13.65 GBX.

Lowest
Price Target
13.13 GBX
19% Upside
Average
Price Target
13.26 GBX
21% Upside
Highest
Price Target
13.65 GBX
24% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Allergy Therapeutics PLC
does not pay dividends
Shareholder Yield

Current shareholder yield for AGY is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y
What is the Intrinsic Value of one AGY stock?

The intrinsic value of one AGY stock under the Base Case scenario is 4.97 GBX.

Is AGY stock undervalued or overvalued?

Compared to the current market price of 11 GBX, Allergy Therapeutics PLC is Overvalued by 55%.

Back to Top